Mercer University Clinical Research Department is proud to offer a large number of clinical trials for patients and potential patients. Our researchers start new trials throughout the year, so the list is updated frequently. For questions regarding a specific clinical trial, please contact the Clinical Research Manager at 478-301-5846, and she will direct you to the appropriate study coordinator.
 

Cardiology

 

  1. Barostim neo®  / BEAT HF – Baroreflex Activation Therapy® for Heart Failure


STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. CACZ885M2301 - A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.


STUDY PHASE: PATIENTS ARE IN FOLLOW UP

                                  

  1. CHAMP-HF - Observational Registry of Treatment Patterns in US Heart Failure Patients with Reduced Ejection Fraction


STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. PIONEER -  A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of Sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patents who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).
     

STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. VICTORIA: - A randomized parallel group placebo controlled double blind event driven multicenter pivotal phase III clinical outcome trial of Efficacy and Safety of the oral sGC Stimulator Veriguat in subjects with heart failure with reduced ejection fraction

 

STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

Infectious Disease
 

  1. GS-US-292-1825 - A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis

 

STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-366-1160- A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz /Emtricitabine/Tenofovir Disoproxil Fumarate(EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects

 

STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-380-1490 - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS- 9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults


STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-380-1844 - Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed


STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-380-1878 - A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults


STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-380-1961 - A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883 / Emtricitabine / Tenofovir Alafenamide (GS-9883/F/TAF) from Elvitegravir /Cobicistat / Emtricitabine / Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir /Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women


STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GS-US-412-2055 - A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection


STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. GSK - LAI116482 - A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naive adult subjects

 

STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GSK- 201637 / SWORD-2 - A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed

 

STUDY PHASE: PATIENTS ARE IN FOLLOW UP

 

  1. GSK - 201584 / FLAIR -  A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants

 

STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. DLS LONGITUDINAL HCV - The Quantitation of HCV RNA in Whole Blood Samples Obtained from Individual Subjects at Specific Time-Points During the Course of Treatment for Hepatitis C

 

STUDY PHASE: PATIENTS ARE BEING ENROLLED

 

  1. SWIMS – Sticking With It Middle and Southern Georgia

STUDY PHASE: PATIENTS ARE BEING ENROLLED